Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration

Archives of Ophthalmology

Volumn 128, Issue 10, 2010, Pages 1273-1279

  Curtis, Lesley H ^a,b   Hammill, Bradley G ^a   Schulman, Kevin A ^a,b   Cousins, Scott W ^c  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY EYE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A;

AGED; ARTICLE; BLEEDING; CARDIOVASCULAR RISK; CAUSE OF DEATH; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEALTH HAZARD; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; STROKE; ANTAGONISTS AND INHIBITORS; EPIDEMIOLOGY; FACTUAL DATABASE; HEMORRHAGE; MACULAR DEGENERATION; MORTALITY; MYOCARDIAL INFARCTION; PHOTOCHEMOTHERAPY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STATISTICS AND NUMERICAL DATA; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; CAUSE OF DEATH; DATABASES, FACTUAL; FEMALE; HEMORRHAGE; HUMANS; MACULAR DEGENERATION; MALE; MEDICARE; MYOCARDIAL INFARCTION; PHOTOCHEMOTHERAPY; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE; UNITED STATES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77958001574     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2010.223     Document Type: Article

References (34)

1. Friedman DS, O'Colmain BJ, Muñoz B, et al; Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122(4):564-572.
2. Ferris FL III, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984;102(11):1640- 1642.
3. Bressler NM; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: twoyear results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol. 2001; 119(2):198-207.
4. Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: twoyear results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - verteporfin in photodynamic therapy report 2. Am J Ophthalmol. 2001;131(5):541-560. (Pubitemid 33734330)
5. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351(27):2805-2816.
6. Kaiser PK; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report no. 8. Graefes Arch Clin Exp Ophthalmol. 2006;244(9):1132-1142.
7. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-1431.
8. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging. 2005;36(4):336-339.
9. Antoszyk AN, Tuomi L, Chung CY, Singh A; FOCUS Study Group. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol. 2008;145(5):862-874.
10. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008;145(2):239-248.
11. Brown DM, Kaiser PK, Michels M, et al; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432-1444.
12. US Food and Drug Administration (FDA) MedWatch. Safety: Avastin (bevacizumab). January 2005. http://www.fda.gov/Safety/MedWatch/ SafetyInformation /SafetyAlertsforHumanMedicalProducts/ucm150721.htm. Accessed August 19, 2009.
13. Michels S. Is intravitreal bevacizumab (Avastin) safe? Br J Ophthalmol. 2006;90 (11):1333-1334.
14. Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med. 2008;358(24):2606-2617.
15. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158(9):915-920.
16. Gutthann SP, García Rodríguez LA, Raiford DS. Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology. 1997;8(1):18-24.
17. White RH, Beyth RJ, Zhou H, Romano PS. Major bleeding after hospitalization for deep-venous thrombosis. Am J Med. 1999;107(5):414-424.
18. Roumie CL, Mitchel E, Gideon PS, Varas-Lorenzo C, Castellsague J, Griffin MR. Validation of ICD-9 codes with a high positive predictive value for incident strokes resulting in hospitalization using Medicaid health data. Pharmacoepidemiol Drug Saf. 2008;17(1):20-26.
19. Birman-Deych E, Waterman AD, Yan Y, Nilasena DS, Radford MJ, Gage BF. Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. Med Care. 2005;43(5):480-485.
20. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130-1139.
21. Prentice RL, Kalbfleisch JD, Peterson AV Jr, Flournoy N, Farewell VT, Breslow NE. The analysis of failure times in the presence of competing risks. Biometrics. 1978;34(4):541-554.
22. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16(3):1141-1154.
23. Iturralde D, Spaide RF, Meyerle CB, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina. 2006;26(3):279-284.
24. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology. 2005;112(6):1035-1047.
25. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina. 2006;26(5):495-511. (Pubitemid 44620390)
26. Spaide RF, Laud KM, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina. 2006;26(4):383-390. (Pubitemid 44197628)
27. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol. 2006;90(11):1344-1349.
28. Ueta T, Yanagi Y, Tamaki Y, Yamaguchi T. Cerebrovascular accidents in ranibizumab. Ophthalmology. 2009;116(2):362.
29. Petri H, Urquhart J. Channeling bias in the interpretation of drug effects. Stat Med. 1991;10(4):577-581.
30. Nguyen-Khoa BA, Goehring EL Jr, Werther W, Gower EW, Do DV, Jones JK. Hospitalized cardiovascular diseases in neovascular age-related macular degeneration. Arch Ophthalmol. 2008;126(9):1280-1286.
31. Duan Y, Mo J, Klein R, et al. Age-related macular degeneration is associated with incident myocardial infarction among elderly Americans. Ophthalmology. 2007;114(4):732-737.
32. Alexander SL, Linde-Zwirble WT, Werther W, et al. Annual rates of arterial thromboembolic events in medicare neovascular age-related macular degeneration patients. Ophthalmology. 2007;114(12):2174-2178. (Pubitemid 350181138)
33. Reed SD, Anstrom KJ, Seils DM, Califf RM, Schulman KA. Use of larger versus smaller drug-safety databases before regulatory approval: the trade-offs. Health Aff (Millwood). 2008;27(5):w360-w370.
34. clinicaltrials.gov. Comparison of age-related macular degeneration treatments trials: Lucentis-Avastin Trial. http://www.clinicaltrials.gov/ct2/ show/NCT00593450. Accessed August 28, 2009.